TMDX$109.12
$109.3
Chart
Performance
Key Stats
AI TMDX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldTransMedics Group shows strong thematic potential and some fundamental strengths, but technical indicators signal caution in the short term. Suitable for investors with moderate risk tolerance and focus on innovation in medical technology.
Thematic
The company leads in innovative organ transplant technology with strong product offerings and high market relevance, particularly with its Organ Care System platform.
Fundamental
The company has improving profitability and solid growth but elevated valuation and debt levels moderate the fundamental appeal.
Technical
The stock exhibits a neutral short-term technical outlook with dominant sell indicators on moving averages, though some oscillators suggest possible buying interest.
| Factor | Score |
|---|---|
| Medical Technology Innovation | 90 |
| Market Leadership & Niche | 75 |
| Growth Opportunity | 70 |
| Regulatory Environment | 65 |
| ESG & Sustainability | 70 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 70 |
| Growth | 85 |
| Balance Sheet Health | 30 |
| Cash Flow | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 45 |
| Momentum | 55 |
| Volume Confirmation | 50 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong Earnings Recovery
The company reported a net income of $35.46 million in 2024Q4 with a positive net margin of 8.0%, a significant turnaround from negative margins in prior years, demonstrating improved profitability.
Rapid Revenue Expansion
Revenue increased to $441.54 million in 2024Q4, nearly doubling from $93.46 million in 2022Q4, indicating strong growth momentum and market demand.
Bearish Points (6)
Extremely High Valuation Multiples
TTM P/E ratio stands at nearly 80 and quarterly P/E ratios spiked as high as 1259.9 in 2024Q3, indicating potentially overvalued shares and heightened risk if growth falters.
Inconsistent and Negative Earnings History
Despite recent positive earnings, the company has reported multiple quarters and years of large losses, including net losses of over $25 million in 2023Q4 and negative EPS surprises in several quarters.
Calendar
July 2025
31
Next Earnings Date
H: $0.59
A: $0.43
L: $0.34
H: 150.00M
A: 146.64M
L: 144.00M
Profile
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Seasonals
Price Target
135.86 USD
The 39 analysts offering 1 year price forecasts for TMDX have a max estimate of 170.00 and a min estimate of 103.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct competitor in RNA-targeted therapies and neurological disorder treatments.
Weight: 95
Leading company in CRISPR-based gene editing, closely related to RNA-based therapeutic technology.
Weight: 93
Focused on gene editing and RNA therapies, strong overlap in biotech innovation field.
Weight: 90
Develops gene editing technologies acting on RNA and DNA; complementary to TMDX focus.